Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
46 hedge funds and large institutions have $267M invested in Sierra Oncology, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
24% more funds holding
Funds holding: 37 → 46 (+9)
15% more capital invested
Capital invested by funds: $233M → $267M (+$34.1M)
3.13% less ownership
Funds ownership: 84.72% → 81.6% (-3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$10.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.93M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$1.89M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.51M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$3.96M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.85M |
| 3 |
Millennium Management
New York
|
-$2.15M |
| 4 |
JSC
Jackson Square Capital
San Francisco,
California
|
-$201K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$95.9K |
SRRA Hedge Fund Activity: Q4 2021 in Review
46 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q4 2021, worth a combined $267M — up 15% from $233M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SRRA positions and 4 closed out — a net gain of 9 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Frazier Management, adding an estimated $10.1M. The largest seller was Caxton Corporation, cutting an estimated $3.96M.
- 46 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q4 2021, up from 37 in Q3 2021.
- Funds reported $267M of Sierra Oncology, Inc. Common Stock stock for Q4 2021, up 15% quarter-over-quarter.
- 13 funds opened new Sierra Oncology, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of +9 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q4 2021 was Frazier Management, an estimated $10.1M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q4 2021 was Caxton Corporation, an estimated $3.96M sold.
Based on aggregated 13F filings for Q4 2021.